(Updated 9th October 2005)
Christopher Paul Berrie
Department of Cell Biology and Oncology
Consorzio Mario Negri Sud
66030 Santa Maria Imbaro Tel: +39-0872-570348
Chieti Fax: +39-0872-570412
Italy E-mail:berrie@dcbo.negrisud.it
Date of Birth: 4October 1956 Nationality: British
Place of Birth: Ibadan,Nigeria MaritalStatus: Married
Natural Sciences Tripos
(Pharmacology Part II)
M.Phil. (CNAA, London);1986
A biochemical andpharmacological investigation of the muscarinic cholinergic receptor insecretory tissue.
Ph.D. (LiverpoolUniversity); 1993
Modulation of calciumsignalling in acinar cells and hepatocytes.
Further Qualifications: Certificate in the Advanced Studyof Education: TEFL/ESP
November 2002 DepartmentalScientific Information Officer
- present Departmentof Cell Biology and Oncology
ConsorzioMario Negri Sud
January 1996 SeniorStaff Researcher
- present Departmentof Cell Biology and Oncology
ConsorzioMario Negri Sud
March 1991 SeniorResearch Associate
- September 1995 Departmentof Human Anatomy and Cell Biology
LiverpoolUniversity, Liverpool, England
July 1989 ResearchAssociate
- February 1991 Departmentof Physiology
ManchesterUniversity, Manchester, England
October 1985 ResearchAssociate
- June 1989 Smith,Kline and French Research Ltd.
TheFrythe, Welwyn, England
August 1978 Technician/ResearchOfficer
- September 1985 Divisionof Molecular Pharmacology
NationalInstitute for Medical Research, London, England
Recent Scientific Collaborations (1999-2005)
(see Research Publications for full references)
Department of Lipid Biochemistry, Institute ofBiomembranes, Utrecht University, Utrecht, Holland.
Snoek et al. (1999) J. Biol. Chem. 274, 35393-35399.
Department of Medicine, UniversityCollege of London, London, UK
Razzini et al. (2000) FASEB J. 14, 1179-1187.
Berrie and Falasca (2000) FASEB J. 14, 2618-2622.
Institute of Biochemistry, University of Lausanne,Switzerland.
Zaru et al. (2001) Eur. J. Immunol. 31, 2438-2447.
Institute for Molecular Cell Biology, University ofAmsterdam, Holland.
Meijer et al. (2001) Biochem. J. 360, 491-498.
Bin Zheng and Marilyn Farquhar
UCSD School of Medicine, La Jolla, California, USA.
Zheng etal.(2003) Proc. Natl. Acad. Sci. USA 100, 1745-1750.
Gabriele Marcolongo and Annalisa Bruno
Marcolongo et al. (2005) Nat. Prod. Res., inpress.
Bruno et al. (2005) Eur. J. Pharmacol., in press.
Further Scientific Experience:
Organising Committee:
FEBS Advanced Course 99-10: Targets and Functions ofLipid-Derived Messengers (June 1999)
FEBS Advanced Course 01-09: Lipid-Mediated Signalling inCellular Functions (June 2001)
Held at: Consorzio Mario Negri Sud, Italy
Society Memberships:
Professional
British Pharmacological Society
Biochemical Society
National Association of Science Writers, Inc. (NASW)
Personal
Campaign for Real Ale (CAMRA; Life Member)
British MotorcyclistsÕ Federation (BMF; Member andex-Regional Representative)
Italian Alpine Club (CAI)
Languages: English (Mother tongue);Italian (good, both spoken and written)
Interests: Sports, including:running, squash, badminton, football, volleyball, tennis. Home brewing,motorcycling, walking, travel, Italy.
(whereindicated, PubMed abstract available through hyperlink)
1.
Guaninenucleotides modulate muscarinic receptor binding in the heart.
Biochem.Biophys. Res. Comm. (1979) 87, 1000-1005.
IF2001: 2.946
2. HammerR,
Pirenzepinedistinguishes between different subclasses of muscarinic receptors.
Nature(1980) 283,90-92.
IF2001: 27.955
3. BirdsallNJM,
Modulationof the binding properties of muscarinic receptors: evidence forreceptor-effector coupling
4. HulmeEC, Birdsall NJM, Berrie CP, Burgen ASV.
Muscarinicreceptor binding: modulation by nucleotides and ions.
In:Neurotransmitters and their Receptors. Editors Littauer, Dudai, Silman,Teichberg, Vogel. J. Wiley and Sons (1980), pp 241-250.
5. BirdsallNJM, Berrie CP, Burgen ASV, Hammer R, Hulme EC, Stockton J.
"BindingStates" of muscarinic receptors.
In:Cholinergic Mechanisms. Editors Pepeu, Ladinsky. Plenum Publishing Corporation,N.Y. (1981), pp 595-599.
6. HulmeEC, Berrie CP, Birdsall NJM, Burgen ASV.
Interactionsof muscarinic receptors with guanine nucleotides and adenylate cyclase.
In:Drug Receptors and their Effectors. Editor Birdsall. Macmillan, London (1981),pp 23-34.
7. BurgenASV, Hulme EC, Berrie CP, Birdsall NJM.
Thenature of muscarinic receptors in the heart.
In:5th Argenteuil Meeting on Cell Membranes in Cardiovascular Physiology andMedicine. Editors Meyer, Godfraind. Elsevier (1981), p 15.
8. Abdul-GhaniAS, Boyar MM, Coutinho-Netto J, Bradford HF,
Effectof Tityus toxin and sensory stimulation on muscarinic cholinergic receptors invivo.
Biochem.Pharmacol. (1981) 30, 2713-2714.
IF2001: 3.340
9. HulmeEC,
Twopopulations of binding sites for muscarinic antagonists in the rat heart.
Eur.J. Pharmacol. (1981) 73, 137-142.
IF2001: 2.164
10. Barany E,
Thebinding properties of the muscarinic receptors of the cynomolgus monkey ciliarybody and the response to the induction of agonist subsensitivity.
Brit.J. Pharmacol. (1982) 77, 731-739.
IF2001: 3.502
11. Hulme EC,
Solubilisationand molecular characterisation of muscarinic acetylcholine receptors.
J.Receptor Res. (1983) 3, 301-311.
IF2001: 2.293
12. Hulme EC,
Regulationof muscarinic agonist binding by cations and guanine nucleotides.
Eur.J. Pharmacol. (1983) 94, 59-72.
IF2001: 2.164
13. BirdsallNJM, Hulme EC, Stockton J, Burgen ASV,
Muscarinicreceptor subclasses: evidence from binding studies.
14. Hulme EC,Birdsall NJM, Berrie CP, Haga T, Stockton JM.
Solubilisationand characterisation of muscarinic acetylcholine receptors.
In:Methodological Surveys in Biochemistry and Analysis. Volume 13: Investigationof membrane located receptors. Editors Reid, Cook, Morre. Plenum PublishingCorporation, N.Y. (1984), p 421.
15.
Hydrodynamicproperties of muscarinic acetylcholine receptors solubilised from ratforebrain.
Brit.J. Pharmacol. (1984) 82, 839-851.
IF2001: 3.502
16.
Solubilisationand characterisation of guanine nucleotide-sensitive muscarinic agonist bindingsites from rat myocardium.
Brit.J. Pharmacol. (1984) 82, 853-861.
IF2001: 3.502
17.
Solubilisationand characterisation of high and low affinity pirenzepine binding sites fromrat cerebral cortex.
Brit.J. Pharmacol. (1985) 85, 697-703.
IF2001: 3.502
18.
Purificationof the muscarinic acetylcholine receptor from rat forebrain.
Biochem.Soc. Trans. (1985) 13, 1101-1103.
IF2001: 1.402
19. BerrieCP,Birdsall NJM, Hulme EC, Keen M, Stockton JM, Wheatley M.
Muscarinicreceptor subclasses: the binding properties of the soluble receptor bindingsites.
Trendsin Pharmacol. Sci. (1986) 7, (2), Suppl. pp 1-6.
IF2001: 11.394
20. HawkinsPT,
Inositol(1,2 cyclic 4,5)-trisphosphate is not a product of muscarinicreceptor-stimulated phosphatidylinositol (4,5)-bisphosphate hydrolysis in ratparotid glands.
Biochem.J. (1987) 243, 211-218.
IF2001: 4.326
21. HardenTK, Berrie CP, Boyer JL, Hawkins PT, Hepler JR, Martin MW, May JM, Morris AJ,Stephens LR, Waldo GL, Downes CP.
G-protein-regulatedphospholipase C: the turkey erythrocyte membrane as a model system.
Proc.10th Int. Congress, Int Union of Pharmacol., August 1987.
22. DownesCP, Berrie CP, Stephens LR, Hawkins PT, Boyer JL, Harden TK.
Receptor-dependentformation and subsequent metabolism of inositol (1,4,5)-trisphosphate.
Proc.of UCLA Symposium, April 1988.
23. DownesCP,
Receptorand G-protein-dependent regulation of turkey erythrocyte phosphoinositidase C.
Phil.Trans. Roy. Soc. (1988) Series B, 320, 267-280.
IF2001: 3.066
24.
Phosphatidylinositol(4,5)-bisphosphate hydrolysis in turkey erythrocytes is regulated by P2Ypurinoceptors.
Molec.Pharmacol. (1989) 35, 526-532.
IF2001: 5.297
25. DownesCP, Berrie CP, Hawkins PT, Boyer JL, Harden TK.
G-protein-dependentregulation of phospholipase C in turkey erythrocyte membranes.
In:Transmembrane Signalling, Intracellular Messengers and Implications for DrugDevelopment. J. Wiley and Sons (1990).
26. StephensLR,
Agonist-stimulatedinositol phosphate metabolism in avian erythrocytes.
Biochem.J. (1990) 269, 65-72.
IF2001: 4.326
27. Ruiz-LarreaF,
Characterizationof a membrane-associated, receptor and G-protein responsive phosphoinositide-specificphospholipase C from avian erythrocytes.
FEBSLett. (1993) 328, 174-182.
IF2001: 3.644
28.
Activationof protein kinase C does not cause desensitization in rat and rabbit mandibularacinar cells.
PflugersArch. (1994) 428, 163-172.
IF2001: 1.632
29. Ruiz-LarreaF, Berrie CP.
Molecularmechanisms of cell growth and oncogene action.
In:Animal Cell Biotechnology. Volume 6. Editors Spier, Griffiths. Academic Press,London (1994), pp215-236
30.
Bothactivators and inhibitors of protein kinase C promote the inhibition ofphenylephrine-induced [Ca2+]i oscillations in singleintact rat hepatocytes.
CellCalcium (1995) 18, 232-244.
IF2001: 3.071
31.
Acytosolic sperm factor triggers calcium oscillations in rat hepatocytes.
Biochem.J. (1996) 313, 369-372.
IF2001: 4.326
32. BerrieCP,Falasca M, Carvelli A, Iurisci, C, Corda D.
Glycerophosphoinositol4-phosphate in intracellular signalling.
In:Frontiers in Bioactive Lipids. Ed. Vanderhoek. Plenum Publishing Corporation,New York (1996), pp229-237.
33.
Solubilizedmuscarinic acetylcholine receptors from the rat myocardium: Pharmacological andhydrodynamic characterisation.
In:Methods in Molecular Biology. Receptor Binding Techniques. Humana Press Inc(1998), pp73-87.
34. MannazzuI, Guerra E, Strabbioli R, Pediconi D, Berrie CP, Fatichenti F.
Recoveryfrom vanadate involves the elimination of cellular structures in the yeast Hansenulapolymorpha.
FoodTechnol. Biotechnol. (1998) 36, 299-303.
IF2001: 0.256
35.
Membranetransport and in vitro metabolism of the Ras cascade messenger,glycerophosphoinositol 4-phosphate.
Eur.J. Biochem. (1999), 266, 413-419.
IF2001: 2.849
36. Snoek GT,
Overexpressionof phosphatidylinositol transfer protein a in NIH3T3 cells activates a phospholipase A.
J.Biol. Chem. (1999) 274, 35393-35399.
IF2001: 7.258
37. BerrieCP,Mancini R, Iurisci C, Corda D.
Secondmessenger functions and metabolism of the glycerophosphoinositols.
In:Molecular Mechanisms of Signal Transduction. Ed. Bos. IOS Press, Amsterdam, TheNetherlands (2000), pp179-186.
38. RazziniG*,
Novelfunctional PI 3-kinase antagonists inhibit cell growth and tumorigenicity inhuman cancer cell lines.
FASEBJ. (2000) 14, 1179-1187.
39.
Patternswithin protein/polyphosphoinositide interactions provide specific targets fortherapeutic intervention.
FASEBJ. (2000) 14, 2618-2622.
IF2001: 8.817
40. Zaru R,
CD28costimulates sustained phosphoinositide turnover by augmentingphosphatidylinositol synthesis.
Eur.J. Immunol. (2001) 31, 2438-2447.
IF2001: 4.990
41. MeijerHJG,
Identificationof a new polyphosphoinositide in plants, phosphatidylinositol 5-monophosphate(PtdIns5P),and its accumulation upon osmotic stress.
Biochem.J. (2001) 360, 491-498.
IF2001: 4.326
42.
Phosphoinositide 3-kinaseinhibition in cancer treatment.
Expert Opin. Invest. Drugs (2001),10,1085-1098.
43. BerrieCP, CordaD.
Rap
In: TheEncyclopaedia of Molecular Medicine. Ed-in-chief Creighton. John Wiley &Sons, New York (2002) pp2728-2732.
44. BerrieCP, CordaD.
Ras
In:The Encyclopaedia of Molecular Medicine. Ed-in-chief Creighton. John Wiley& Sons, New York (2002) pp2732-2735.
45. Corda D, Iurisci C,
The biological activities of theglycerophosphoinositols and lysophosphatidylinositols in normal and transformedcells.
Biochim.Biophys. Acta (2002) 1582, 52-69.
IF2001: 8.550
46.
Maintenanceof PtdIns45P2 pools under limiting inositol conditions, as assessedby liquid chromatography-tandem mass spectrometry and PtdIns45P2mass evaluation in Ras-transformed cells.
Eur.J. Cancer (2002)
IF2001: 3.460
47. Lupi R,Dani N, Dietrich A, Marchegiani A, Turacchio S,
Endogenousmono-ADP-ribosylation of the free Gbg prevents stimulation of phosphoinositide 3-kinase-
Biochem.J.
IF2001: 4.326
48. Zheng B,
MIR16,a membrane glycerophosphodiester phosphodiesterase: Membrane topology, enzymaticactivity, and implications for membrane trafficking and signaling.
Proc.Natl. Acad. Sci. USA (2003) 100, 1745-1750.
IF2001: 10.896
49. ManciniR, Piccolo E, Mariggiò S, Filippi B, Iurisci C, Pertile P, Berrie CP, Corda D.
Thephosphoinositide metabolite glycerophosphoinositol 4-phosphate induces actinruffles by activating Rac.
Mol.Biol. Cell (2003) 14, 503-515.
IF2001: 7.700
50. DraganiLK, Berrie CP, Corda D, Rotilio D.
Analysisof glycerophosphoinositols by liquid chromatography-electrospray ionisationtandem mass spectrometry using a b-cyclodextrin-bonded column.
J.Chromatogr. B (2004) 802, 283-289.
IF2001: 1.911
51. MarcolongoG, De Appolonia F, Venzo A, Berrie CP, Carofiglio T, Ceschi Berrini C.
Diacylglycerolipidsisolated from a thermophile cyanobacterium from the Euganean hot springs.
Nat.Prod. Res., (2005) in press.
52. Bruno A,Rossi C, Di Lena A, Marcolongo G, Berrie CP, Corda D.
Selectivein vivoanti-inflammatory action of the cyanobacterium galactolipidmonogalactosyldiacylglycerol.
Eur.J. Pharmacol., (2005) in press.
53. Berrie CP, Iurisci C, Bagnati R,Piccolo E, Mariggiò S, Corda D.
Apractical methodological review to the separation, identification andquantification of phosphoinositides and their aqueous derivatives.
Prog.Lip. Res., submitted.
IF:10.0
1.
Ionicperturbation of agonist binding to brain muscarinic receptors.
Brit.J. Pharmacol. (1979) 66, 470P-471P.
IF2001: 3.502
2. BirdsallNJM, Hulme EC, Burgen ASV, Berrie CP, Hammer R.
Theantisecretory agent pirenzepine shows an original spectrum of bindingproperties to muscarinic receptors.
HepatogastroenterologySuppl. (1980) p 183.
IF2001: 0.886
3. BerrieCP,Birdsall NJM, Bloxham CA, Hulme EC.
Solubilisationof human striatal dopamine (D2) receptors.
Brit.J. Pharmacol. (1983) 78, 7P.
IF2001: 3.502
4. BerrieCP,Birdsall NJM, Burgen ASV, Hulme EC.
Divalentcations regulate the receptor-specific binding of muscarinic agonists.
Brit.J. Pharmacol. (1983) 78, 66P.
IF2001: 3.502
5. BerrieCP,Birdsall NJM, Burgen ASV, Hulme EC.
Thebinding properties of muscarinic receptors in the rat lacrimal gland:comparison with the cerebral cortex and myocardium.
Brit.J. Pharmacol. (1983) 78, 67P.
IF2001: 3.502
6. HulmeEC, Berrie CP, Birdsall NJM, Haga T, Stockton JM.
Solubilisation,molecular characterisation and purification of muscarinic acetylcholinereceptors.
J.Neurochem. (1983) 41, 5126.
IF2001: 4.834
7. BerrieCP,Birdsall NJM, Hulme EC, Wheatley M.
Purificationof the muscarinic acetylcholine receptor from rat cerebral cortex.
IUPHAR9th International Congress of Pharmacology (1984), 155P.
8. BerrieCP,Birdsall NJM, Hulme EC, Keen M, Stockton JM.
Pirenzepinebinding to solubilised muscarinic receptors from rat cerebral cortex andmyocardium.
Brit.J. Pharmacol. (1985) 84, 4P.
IF2001: 3.502
9. BerrieCP,Elliott AC.
Differentialeffects of a phorbol ester on acetylcholine-evoked changes in [Ca2+]iin single acini isolated from rat lacrimal and rabbit mandibular gland.
J.Physiol. (1990) 429, 89P.
IF2001: 4.476
10. BerrieCP,Elliott AC.
Thephorbol ester TPA inhibits muscarinic responses in rat lacrimal acinar cellsbut not in rabbit salivary acinar cells.
Brit.J. Pharmacol. (1990) 101, 501P.
IF2001: 3.502
11. BerrieCP,Falasca M, Marino M, Carvelli A, Iurisci C, Leoni S, Corda D.
Furtherevidence of a second messenger role for glycerophosphoinositol 4-phosphate.
In:XVIth Washington International Spring Symposium. "Frontiers in BioactiveLipids", Washington, May 1996, p32.
12. FalascaM, Berrie CP, Carvelli A, Iurisci C, Corda D.
Mechanismof action and metabolism of glycerophosphoinositol 4-phosphate, a putativenovel intracellular messenger in the Ras pathway.
In:Cell Signalling Mechanisms, Amsterdam, June 1997.
13. BerrieCP,Mancini R, Iurisci C, Marchegiani A, Falasca M, Corda D.
Signallingactivities of glycerophosphoinositols.
AnticancerRes.(1998), 18 (6C), 4847.
IF2001: 1.416